NewAmsterdam Pharma Co N.V.
NAMS$3.79B
Mid CapNASDAQBiotechnology🇺🇸North America68 employees
Drugs in Pipeline
8
Phase 3 Programs
4
Upcoming Catalysts
3
Next Catalyst
Sep 15, 2026
26wMarket Overview
Stock performance and key metrics
NAMS News
Catalyst Timeline
3 upcoming, 1 past
Drug Pipeline
obicetrapib 10 mg + ezetimibe 10 mg FDC daily
Lipidemia
Monotherapy obicetrapib
Dyslipidemias
Obicetrapib
Dyslipidemias
Obicetrapib 10 mg
Lipidemia
obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks
Dyslipidemias
Obicetrapib 5mg
Dyslipidemias
Ezetimibe 10mg
Dyslipidemias
Obicetrapib 10mg
Antioxidant Absorption
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
obicetrapib 10 mg + ezetimibe 10 mg FDC daily | Phase 3 | Lipidemia | - | - |
Monotherapy obicetrapib | Phase 3 | Dyslipidemias | - | - |
Obicetrapib | Phase 3 | Dyslipidemias | - | - |
Obicetrapib 10 mg | Phase 3 | Lipidemia | - | - |
obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks | Phase 2 | Dyslipidemias | - | - |
Obicetrapib 5mg | Phase 2 | Dyslipidemias | - | - |
Ezetimibe 10mg | Phase 2 | Dyslipidemias | - | - |
Obicetrapib 10mg | Phase 2 | Antioxidant Absorption | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply